Altimmune 과거 수익 실적

NasdaqGM:ALT 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	0	-101	20
31 Mar 24	0	-93	19
31 Dec 23	0	-88	18
30 Sep 23	0	-78	18
30 Jun 23	0	-81	18
31 Mar 23	0	-85	17
31 Dec 22	0	-85	17
30 Sep 22	3	-87	17
30 Jun 22	3	-97	17
31 Mar 22	4	-102	16
31 Dec 21	4	-97	15
30 Sep 21	3	-84	16
30 Jun 21	6	-68	16
31 Mar 21	7	-60	15
31 Dec 20	8	-49	13
30 Sep 20	6	-43	11
30 Jun 20	4	-36	9
31 Mar 20	5	-22	9
31 Dec 19	6	-21	9
30 Sep 19	8	-42	9
30 Jun 19	10	-34	9
31 Mar 19	11	-40	9
31 Dec 18	10	-42	10
30 Sep 18	11	-29	9
30 Jun 18	13	-58	10
31 Mar 18	13	-52	10
31 Dec 17	11	-51	8
30 Sep 17	9	-43	8
30 Jun 17	5	-16	8
31 Mar 17	3	-14	7
31 Dec 16	3	-11	6
30 Sep 16	3	-10	5
31 Dec 15	5	-7	5
31 Dec 14	6	-1	1

양질의 수익: ALT 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALT 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ALT 은(는) 수익성이 없으며 지난 5년 동안 연간 21.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ALT 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALT 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ALT 현재 수익성이 없기 때문에 마이너스 자본 수익률( -66.44% )을 갖습니다.

Altimmune 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Recent updates

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune

Altimmune sets new 52-week high on rising volume

Consensus forecasts updated

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Price target increased to US$24.86

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune Q2 2022 Earnings Preview